Evidence map›Paper›PMID 18314433›Full record

Trial reportJAMA2008

Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

David Brent, Graham Emslie, Greg Clarke, Karen Dineen Wagner, Joan Rosenbaum Asarnow, Marty Keller, Benedetto Vitiello, Louise Ritz, Satish Iyengar, Kaleab Abebe and 14 more

Erratum issued 6 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 6 registered trials, which are not on this map. Cited by 229 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
229citing papers in PubMed, 12 pooled it
59.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00018902 phase2 / phase3completednot on this map

Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)

TypeinterventionalSponsorUniversity of PittsburghRan2001 to 2007Enrolled334ConditionsDepressionArmsFluoxetine, Venlafaxine, Cognitive Behavioral Therapy (CBT), Citalopram
NCT03925038 nacompletednot on this mapstarted 2019, after this paper: background citation

The Use of Electronic Communications-based Automated Technologies to Augment Traditional Mental Health Care

TypeinterventionalSponsorJohns Hopkins UniversityRan2019 to 2024Enrolled103ConditionsDepressive Disorder, Anxiety Disorders, Bipolar Affective DisorderArmsAugmented Care: Electronic Media Dashboard, Treatment as Usual
NCT05390918 narecruitingnot on this mapstarted 2022, after this paper: background citation

Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior

TypeinterventionalSponsorJeff BridgeRan2022 to 2027Enrolled235ConditionsInsomnia, Suicidal Ideation, Suicide, AttemptedArmsTAILOR, Enhanced Usual Care
NCT05814640 phase1 / phase2recruitingnot on this mapstarted 2023, after this paper: background citation

Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD): a Pragmatic Clinical Trial

TypeinterventionalSponsorFirst Affiliated Hospital of Chongqing Medical UniversityRan2023 to 2027Enrolled520ConditionsDepression, SequestraArmsFluoxetine, Sertraline, Vortioxetine, Duloxetine, Aripiprazole
NCT06018285 narecruitingnot on this mapstarted 2023, after this paper: background citation

Stepped Approach to Reducing Risk of Suicide in Primary Care

TypeinterventionalSponsorCynthia FontanellaRan2023 to 2027Enrolled2,572ConditionsSuicidal Ideation, Suicide, Attempted, Suicide PreventionArmsStepped Approach to Reducing Risk of Suicide in Primary Care
NCT07185438 narecruitingnot on this mapstarted 2025, after this paper: background citation

Feasibility, Safety, and Preliminary Clinical Efficacy of Magnetic Resonance Imaging-guided Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression: A Randomized, Double-Blind, Controlled Pilot Study

TypeinterventionalSponsorFirst Affiliated Hospital of Chongqing Medical UniversityRan2025 to 2027Enrolled45ConditionsDepression - Major Depressive DisorderArmsExperimental target rTMS treatment, Conventional target rTMS treatment, Sham stimulation treatment
3 · Its place in the literature

Who cites it

229 citing papers in PubMed, 12 syntheses or guidelines pooled it, 690 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Intervention for marijuana using, court-involved non-incarcerated youth.Journal of substance use and addiction treatment · 2023
    Trial
  17. Trajectories of Treatment Response and Nonresponse in Youth at High Risk for Suicide.Journal of the American Academy of Child and Adolescent Psychiatry · 2022
    Trial
  18. Trial
  19. Trial
  20. A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression.Journal of the American Academy of Child and Adolescent Psychiatry · 2022
    Trial

169 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 1 country.

David Brent
Graham Emslie
Greg Clarke
Karen Dineen Wagner
Joan Rosenbaum Asarnow
Marty Keller
Benedetto Vitiello
Louise Ritz
Satish Iyengar
Kaleab Abebe
Boris Birmaher
Neal Ryan
Betsy Kennard
Carroll Hughes
Lynn DeBar
James McCracken
Michael Strober
Robert Suddath
Anthony Spirito
Henrietta Leonard
Nadine Melhem
Giovanna Porta
Matthew Onorato
Jamie Zelazny
University of Pittsburgh · USUniversity of California, Los Angeles · USJohn Brown University · USKaiser Permanente · USNational Institutes of Health · USThe University of Texas Medical Branch at Galveston · US

Funding

Core--Research network developmentP30MH066371 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BRENT, DAVID A. · 2002 to 2006
$8.2M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061835 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BRENT, DAVID A. · 2000 to 2006
$3.3M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061869 · NIMH · KAISER FOUNDATION RESEARCH INSTITUTE · PI CLARKE, GREGORY N · 2000 to 2006
$2.8M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061856 · NIMH · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WAGNER, KAREN D · 2000 to 2006
$1.9M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061958 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI EMSLIE, GRAHAM J. · 2000 to 2006
$1.8M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061864 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ASARNOW, JOAN ROSENBAUM · 2000 to 2006
$1.5M
TREATMENT OF SSRI-RESISTANT DEPRESSION IN ADOLESCENTSU01MH062014 · NIMH · BROWN UNIVERSITY · PI KELLER, MARTIN B · 2000 to 2006
$1.5M
NIMH NIH HHS MH61835NIMH NIH HHS MH61856NIMH NIH HHS MH61864NIMH NIH HHS MH61869NIMH NIH HHS MH61958NIMH NIH HHS MH62014NIMH NIH HHS MH66371NIMH NIH HHS P30 MH066371NIMH NIH HHS U01 MH061835NIMH NIH HHS U01 MH061856NIMH NIH HHS U01 MH061864NIMH NIH HHS U01 MH061869NIMH NIH HHS U01 MH061958NIMH NIH HHS U01 MH062014
6 · The paper itself

Abstract

contextOnly about 60% of adolescents with depression will show an adequate clinical response to an initial treatment trial with a selective serotonin reuptake inhibitor (SSRI). There are no data to guide clinicians on subsequent treatment strategy.

objectiveTo evaluate the relative efficacy of 4 treatment strategies in adolescents who continued to have depression despite adequate initial treatment with an SSRI. DESIGN, SETTING, AND

participantsRandomized controlled trial of a clinical sample of 334 patients aged 12 to 18 years with a primary diagnosis of major depressive disorder that had not responded to a 2-month initial treatment with an SSRI, conducted at 6 US academic and community clinics from 2000-2006.

interventionsTwelve weeks of: (1) switch to a second, different SSRI (paroxetine, citalopram, or fluoxetine, 20-40 mg); (2) switch to a different SSRI plus cognitive behavioral therapy; (3) switch to venlafaxine (150-225 mg); or (4) switch to venlafaxine plus cognitive behavioral therapy.

main outcome measuresClinical Global Impressions-Improvement score of 2 or less (much or very much improved) and a decrease of at least 50% in the Children's Depression Rating Scale-Revised (CDRS-R); and change in CDRS-R over time.

resultsCognitive behavioral therapy plus a switch to either medication regimen showed a higher response rate (54.8%; 95% confidence interval [CI], 47%-62%) than a medication switch alone (40.5%; 95% CI, 33%-48%; P = .009), but there was no difference in response rate between venlafaxine and a second SSRI (48.2%; 95% CI, 41%-56% vs 47.0%; 95% CI, 40%-55%; P = .83). There were no differential treatment effects on change in the CDRS-R, self-rated depressive symptoms, suicidal ideation, or on the rate of harm-related or any other adverse events. There was a greater increase in diastolic blood pressure and pulse and more frequent occurrence of skin problems during venlafaxine than SSRI treatment.

conclusionsFor adolescents with depression not responding to an adequate initial treatment with an SSRI, the combination of cognitive behavioral therapy and a switch to another antidepressant resulted in a higher rate of clinical response than did a medication switch alone. However, a switch to another SSRI was just as efficacious as a switch to venlafaxine and resulted in fewer adverse effects.

trial registrationclinicaltrials.gov Identifier: NCT00018902.

Indexed as

Cognitive Behavioral TherapyAdolescentCitalopramCombined Modality TherapyCyclohexanolsDrug ResistanceFemaleFluoxetineHumansMajor Depressive DisorderMaleParoxetineSelective Serotonin Reuptake InhibitorsTreatment OutcomeVenlafaxine HydrochlorideCitalopramCyclohexanolsFluoxetineParoxetineSelective Serotonin Reuptake InhibitorsVenlafaxine Hydrochloride

Identifiers

PMID18314433
PMCPMC2277341
OpenAlexW2113281483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.